13/11/2017 17:47h .
Elena Gregori @ib3noticies
13 noviembre 2017
PharmaMar, An Innovative Oncology Company.
PharmaTimes , Online . 13th November 2017.PharmaMar is one of the few biopharmaceutical companies to have a product on the market, another awaiting commercialisation and various more at different stages of clinical development.
With more than 30 years of experience in marine biomedicine, they are the first company to carry out all the different phases of development of a drug of these characteristics and bring it to commercialisation. PharmaMar is an integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Thanks to their “know how” and a solid and proven experience, today they are a global leader in their sector.
Since 2007, the Company’s compound therapy for soft tissue sarcoma and platinum sensitive ovarian cancer has become available in 80 countries; the first time an antitumoural drug of a marine origin had been authorised.
An international company :
PharmaMar is a biopharmaceutical company focused on oncology, with its head office in Madrid, Spain and a growing network of affiliates around the world. The internationalisation of the company is and has been a constant since their creation in 1986. From the start, they have understood that the access to knowledge around the world is fundamental to establish both scientific and commercial collaborations that would lead to both a solid and sustainable growth.
The process of expansion beyond Spanish borders started in 1999 with the opening of an office in the USA. Between 2012 and 2017, the necessary decisions to drive towards internationalisation were made; the Company wanting to maintain a direct presence in key countries to be able to continue with its growth. During this time offices have been opened in Italy, Germany, Switzerland, France, the United Kingdom, Belgium and Austria.
Committed with patients :
PharmaMar currently has 232 qualified personnel working in Research and Development and Clinical Development functions. They are working on a rich pipeline focused on treating several diseases such as small-cell lung cancer, multiple myeloma, platinum-resistant ovarian cancer, breast cancer, endometrial cancer or angioimmunoblastic T-cell lymphoma with novel mechanisms of action.
Nowadays they have several studies ongoing in these diseases. The company already collaborates with many hospitals in the UK.
In advanced and relapsed small-cell lung cancer, their compound is under investigation in a phase III trial with 600 patients in 20 countries. This is an indication that has a poor prognosis and patients need therapeutic alternatives.
PharmaMar invests significantly in drug research and development. In 2016, the company’s financial position funded an increase in R&D expenditure by 30% when compared with 2015 to finance ongoing clinical research of the molecules at various stages of development.
PharmaMar´s future :
Over the next five years, PharmaMar hopes to bring three molecules, across five different indications, to market; aiming to positively challenge the perception of what is possible in drug delivery, pioneer innovative new treatments and, above all, transform the lives of patients around the world.
Zepsyre - CTOS 17 . Lurbinectedin shows activity in pretreated Ewing sarcoma .
P.J.: Zepsyre ya ha Demostrado Actividad en Ovario, Mama, Pulmón , Endometrio ... Y ahora también en Sarcoma de Ewing .
********
CTOS // November 12, 2017 // WAILEA, Hawaii .
Lurbinectedin Muestra Actividad en el Sarcoma de Ewing Pretratado .
*.- "Lurbinectedin como agente único muestra actividad alentadora en el sarcoma de Ewing avanzado, para el cual hay una necesidad médica no satisfecha".
*.- Ningún Paciente se Retiró o Murió debido a la Toxicidad.
*.- "El tratamiento en combinación con otros agentes está garantizado en esta población de pacientes".
Single-agent lurbinectedin induced partial responses among patients with advanced Ewing sarcoma, according to results of multicenter phase 2 basket study presented at the Connective Tissue Oncology Society Annual Meeting.
New therapeutic agents with different mechanisms of action are needed for Ewing sarcoma, because patients with advanced or relapsed disease have poor outcomes.
“Lurbinectedin (PM1183, PharmaMar) is a novel anticancer drug that inhibits active transcription of protein-coding genes and modulates the tumor microenvironment,” Vivek Subbiah, MD, assistant professor in the department of investigational cancer therapeutics at The University of Texas MD Anderson Cancer Center, said during his presentation.
Subbiah and colleagues evaluated the safety and efficacy of lurbinectedin in a basket trial of patients with several types of advanced solid tumors.
The current analysis included 25 adults (median age, 30 years; range, 18-74; men, n = 14) from a cohort of patients with Ewing sarcoma who received two or fewer prior chemotherapy-containing regimens. Twenty-three patients had an ECOG performance status of 0 or 1. Thirteen patients had extraosseous tumors, and six patients had three or more disease sites.
Patients received 3.2 mg/m2 lurbinectedin in a 1-hour infusion every 3 weeks. Twenty-three patients received a median of two cycles (range, 1-9), with a median total dose of 6.6 mg/m2 (range, 3.2-28.2).
Seventeen patients had data evaluable for efficacy, three of whom had a partial response. Eight patients achieved stable disease, which lasted for 3 months or longer for four patients. Median duration of response was 2.9 months (range, +1.5-5.5).
Median PFS was 4.1 months (95% CI, 1.4-5.1).
Most adverse events were related to myelosuppression, which included grade 3 and grade 4 neutropenia (50%), febrile neutropenia (13%) and thrombocytopenia (13%). Five patients experienced dose delay due to grade 2 to grade 4 neutropenia or grade 2 thrombocytopenia.
Four patients had dose reduction due to grade 4 neutropenia. Ten patients received granulocyte-colony stimulating factor to manage toxicities.
No patient withdrew due to or died of toxicity.
“Lurbinectedin as a single agent shows encouraging activity in advanced Ewing sarcoma, for which there is an unmet medical need,” Subbiah said. “Treatment in combination with other agents is warranted in this patient population.” – by Alexandra Todak
********
CTOS // November 12, 2017 // WAILEA, Hawaii .
Lurbinectedin Muestra Actividad en el Sarcoma de Ewing Pretratado .
*.- "Lurbinectedin como agente único muestra actividad alentadora en el sarcoma de Ewing avanzado, para el cual hay una necesidad médica no satisfecha".
*.- Ningún Paciente se Retiró o Murió debido a la Toxicidad.
*.- "El tratamiento en combinación con otros agentes está garantizado en esta población de pacientes".
Single-agent lurbinectedin induced partial responses among patients with advanced Ewing sarcoma, according to results of multicenter phase 2 basket study presented at the Connective Tissue Oncology Society Annual Meeting.
New therapeutic agents with different mechanisms of action are needed for Ewing sarcoma, because patients with advanced or relapsed disease have poor outcomes.
“Lurbinectedin (PM1183, PharmaMar) is a novel anticancer drug that inhibits active transcription of protein-coding genes and modulates the tumor microenvironment,” Vivek Subbiah, MD, assistant professor in the department of investigational cancer therapeutics at The University of Texas MD Anderson Cancer Center, said during his presentation.
Subbiah and colleagues evaluated the safety and efficacy of lurbinectedin in a basket trial of patients with several types of advanced solid tumors.
The current analysis included 25 adults (median age, 30 years; range, 18-74; men, n = 14) from a cohort of patients with Ewing sarcoma who received two or fewer prior chemotherapy-containing regimens. Twenty-three patients had an ECOG performance status of 0 or 1. Thirteen patients had extraosseous tumors, and six patients had three or more disease sites.
Patients received 3.2 mg/m2 lurbinectedin in a 1-hour infusion every 3 weeks. Twenty-three patients received a median of two cycles (range, 1-9), with a median total dose of 6.6 mg/m2 (range, 3.2-28.2).
Seventeen patients had data evaluable for efficacy, three of whom had a partial response. Eight patients achieved stable disease, which lasted for 3 months or longer for four patients. Median duration of response was 2.9 months (range, +1.5-5.5).
Median PFS was 4.1 months (95% CI, 1.4-5.1).
Most adverse events were related to myelosuppression, which included grade 3 and grade 4 neutropenia (50%), febrile neutropenia (13%) and thrombocytopenia (13%). Five patients experienced dose delay due to grade 2 to grade 4 neutropenia or grade 2 thrombocytopenia.
Four patients had dose reduction due to grade 4 neutropenia. Ten patients received granulocyte-colony stimulating factor to manage toxicities.
No patient withdrew due to or died of toxicity.
“Lurbinectedin as a single agent shows encouraging activity in advanced Ewing sarcoma, for which there is an unmet medical need,” Subbiah said. “Treatment in combination with other agents is warranted in this patient population.” – by Alexandra Todak
PharmaMar . Daedophamide, a Cytotoxic Cyclodepsipeptide from a Daedalopelta sp. Sponge Collected in Indonesia.
J Nat Prod. 2017 Nov 7.
Urda C1, Fernández R1, Rodríguez J2, Pérez M1, Jiménez C2, Cuevas C1.
Author information :
1 = Medicinal Chemistry Department, PharmaMar S. A. , Pol. Ind. La Mina Norte, Avenida de los Reyes 1, 28770, Colmenar Viejo (Madrid), Spain.
2 = Departamento de Química, Facultade de Ciencias e Centro de Investigacións Científicas Avanzadas (CICA), Universidade da Coruña , 15071 A Coruña, Spain.
Abstract
A new cyclodepsipeptide, daedophamide (1), has been isolated from a Daedalopelta sp. marine sponge collected from Alor Island (Indonesia). The planar structure of 1 was assigned on the basis of extensive 1D and 2D NMR spectroscopy and mass spectrometry. Daedophamide (1) contains 11 amino acid residues and an amide-linked 3-hydroxy-2,4,6,8-tetramethylnonanoic acid (Htemna). The amino acid constituents were identified as l-Leu, N-Me-l-Gln, d-Arg, d-Asp, d-allo-Thr, l-Pip, d-Ala, d-Ser, 3,4-dimethyl-Gln, O-MeThr, and 4-amino-7-guanidino-2,3-dihydroxyheptanoic acid (Agdha). The absolute configurations of eight of the amino acid residues in 1 were determined by application of the Marfey's method after acid-catalyzed hydrolysis, with the relative configurations of the remaining three amino acid residues and the Htemna unit being assigned by comparison of the NMR data with those reported for other similar peptides. Compound 1 displayed strong cytotoxic activity against a panel of four human tumor cell lines with GI50 values in the submicromolar range.
Urda C1, Fernández R1, Rodríguez J2, Pérez M1, Jiménez C2, Cuevas C1.
Author information :
1 = Medicinal Chemistry Department, PharmaMar S. A. , Pol. Ind. La Mina Norte, Avenida de los Reyes 1, 28770, Colmenar Viejo (Madrid), Spain.
2 = Departamento de Química, Facultade de Ciencias e Centro de Investigacións Científicas Avanzadas (CICA), Universidade da Coruña , 15071 A Coruña, Spain.
Abstract
A new cyclodepsipeptide, daedophamide (1), has been isolated from a Daedalopelta sp. marine sponge collected from Alor Island (Indonesia). The planar structure of 1 was assigned on the basis of extensive 1D and 2D NMR spectroscopy and mass spectrometry. Daedophamide (1) contains 11 amino acid residues and an amide-linked 3-hydroxy-2,4,6,8-tetramethylnonanoic acid (Htemna). The amino acid constituents were identified as l-Leu, N-Me-l-Gln, d-Arg, d-Asp, d-allo-Thr, l-Pip, d-Ala, d-Ser, 3,4-dimethyl-Gln, O-MeThr, and 4-amino-7-guanidino-2,3-dihydroxyheptanoic acid (Agdha). The absolute configurations of eight of the amino acid residues in 1 were determined by application of the Marfey's method after acid-catalyzed hydrolysis, with the relative configurations of the remaining three amino acid residues and the Htemna unit being assigned by comparison of the NMR data with those reported for other similar peptides. Compound 1 displayed strong cytotoxic activity against a panel of four human tumor cell lines with GI50 values in the submicromolar range.
Genomica SAU ( Grupo PharmaMar ) en el Congreso Medica 2017 .
GENOMICA asistirá a MEDICA 2017 .
La compañía de diagnóstico española volverá a Düsseldorf a uno de los congresos de medicina más importantes del mundo.
Con más de cuarenta años de antigüedad este congreso reúne anualmente a unos 100.000 asistentes de más de 70 países. El año pasado se dieron cita 5.100 expositores que presentaron productos relacionados con la electrónica médica, el diagnóstico, consumibles para hospital, fisioterapia, sistemas de comunicación e información clínica y servicios médicos.
GENOMICA exhibirá sus últimos avances en el hall 3, stand 3A42 que comparte, ya tradicionalmente, con la compañía alemana Scienion.
Con más de cuarenta años de antigüedad este congreso reúne anualmente a unos 100.000 asistentes de más de 70 países. El año pasado se dieron cita 5.100 expositores que presentaron productos relacionados con la electrónica médica, el diagnóstico, consumibles para hospital, fisioterapia, sistemas de comunicación e información clínica y servicios médicos.
GENOMICA exhibirá sus últimos avances en el hall 3, stand 3A42 que comparte, ya tradicionalmente, con la compañía alemana Scienion.
Global Multiple Myeloma Drugs Market Analysis by Top Key Players, Industry Overview, Supply and Consumption Demand Analysis to 2022 .
By Arun Patil On November 13, 2017.
Global Multiple Myeloma Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Bristol Myers Squibb
...
Global Multiple Myeloma Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Bristol Myers Squibb
...
Suscribirse a:
Entradas (Atom)